T Cell: 13286 Clinical Trials, Page 21 of 1329

Hide Studies Not Open or Pending

204

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Condition(s):Juvenile Myelomonocytic Leukemia; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Undifferentiated Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Adult Acute Lymphoblastic Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; Recurrent Myelodysplastic Syndrome; Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm; Refractory Myelodysplastic Syndrome; Acute Undifferentiated Leukemia; Mixed Phenotype Acute Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Myelodysplastic Syndrome; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Biphenotypic Leukemia; Chronic Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Minimal Residual Disease; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Mixed Phenotype Acute Leukemia; LeukemiaLast Updated:March 21, 2024Suspended

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.